Genmab A/S (NASDAQ:GMAB) Stock Sees Unusually High Call Option Buying

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the recipient of some unusual options trading on Thursday. Traders purchased 24,213 call options on the stock. This is an increase of 485% compared to the typical daily volume of 4,137 call options.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GMAB shares. JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday, October 26th. Morgan Stanley upped their target price on shares of Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Friday, October 30th. HC Wainwright increased their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Guggenheim lifted their price target on shares of Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, TD Cowen boosted their price objective on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $53.61.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded down $1.51 during trading on Thursday, reaching $52.35. 3,495,348 shares of the company traded hands, compared to its average volume of 2,558,773. The firm has a 50 day simple moving average of $40.46 and a 200-day simple moving average of $31.43. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $32.67 billion, a PE ratio of 44.75, a P/E/G ratio of 2.18 and a beta of 0.73. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $59.97.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in Genmab A/S by 3.0% in the 3rd quarter. Parallel Advisors LLC now owns 6,274 shares of the company’s stock worth $224,000 after purchasing an additional 183 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Genmab A/S by 38.6% during the third quarter. Bessemer Group Inc. now owns 729 shares of the company’s stock valued at $26,000 after buying an additional 203 shares during the last quarter. Park Avenue Securities LLC raised its position in shares of Genmab A/S by 2.4% during the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock valued at $402,000 after buying an additional 265 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Genmab A/S by 4.5% in the third quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock worth $436,000 after buying an additional 523 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 16.4% in the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after buying an additional 561 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.